Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Limited is engaged in the marketing of pharmaceutical products in domestic and international markets. The company is also engaged in distribution of pharmaceutical products through third-party distribution network.[1]It is a part of the Trident Texofab Group
- Market Cap ₹ 229 Cr.
- Current Price ₹ 199
- High / Low ₹ 240 / 131
- Stock P/E 32.5
- Book Value ₹ 45.8
- Dividend Yield 0.00 %
- ROCE 20.9 %
- ROE 15.4 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.55%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
4.93 | 9.62 | 21.77 | 31.69 | 44.65 | |
5.20 | 8.37 | 19.05 | 25.42 | 35.82 | |
Operating Profit | -0.27 | 1.25 | 2.72 | 6.27 | 8.83 |
OPM % | -5.48% | 12.99% | 12.49% | 19.79% | 19.78% |
0.07 | 0.16 | 0.60 | 1.15 | 2.20 | |
Interest | 0.76 | 0.41 | 0.13 | 0.48 | 0.46 |
Depreciation | 0.12 | 0.14 | 0.20 | 0.36 | 0.77 |
Profit before tax | -1.08 | 0.86 | 2.99 | 6.58 | 9.80 |
Tax % | 25.93% | 25.58% | -32.11% | 8.51% | 28.06% |
-0.80 | 0.63 | 3.95 | 6.01 | 7.04 | |
EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.12 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 67% |
TTM: | 41% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 124% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 23% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 3.10 | 5.00 | 8.00 | 11.50 | 11.50 |
Reserves | -6.10 | -5.47 | -3.22 | 34.13 | 41.18 |
6.46 | 4.53 | 2.46 | 3.38 | 6.19 | |
2.93 | 7.39 | 6.59 | 7.49 | 14.37 | |
Total Liabilities | 6.39 | 11.45 | 13.83 | 56.50 | 73.24 |
0.77 | 1.18 | 1.43 | 3.11 | 7.62 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.23 | 4.03 |
Investments | 0.00 | 0.00 | 0.05 | 4.04 | 4.40 |
5.62 | 10.27 | 12.35 | 49.12 | 57.19 | |
Total Assets | 6.39 | 11.45 | 13.83 | 56.50 | 73.24 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
-0.59 | 1.48 | -0.19 | -16.60 | 0.90 | |
-0.08 | -0.56 | -0.50 | -5.56 | -11.01 | |
0.76 | -0.96 | 0.80 | 35.80 | 2.35 | |
Net Cash Flow | 0.08 | -0.03 | 0.11 | 13.64 | -7.76 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 96.99 | 24.28 | 83.33 | 139.94 | |
Inventory Days | 103.66 | 349.10 | 95.16 | 129.36 | |
Days Payable | 201.80 | 266.30 | 134.15 | 86.78 | |
Cash Conversion Cycle | -1.15 | 107.09 | 44.34 | 182.52 | |
Working Capital Days | -11.85 | 11.76 | 66.73 | 307.18 | |
ROCE % | 33.78% | 55.22% | 25.10% |
Documents
Announcements
- Closure of Trading Window 24h
- Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011 1d
- Disclosure As Per Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 1d
- Disclosure As Per Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 1d
- Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011 1d
Business categories[1]
1. Ethical marketing of pharmaceutical formulation & products in International Markets through a third-party distribution network and sales force under its own brand
2. Getting approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic Pharma formulation and medicines in Domestic and International Market.
The company is working on Asset-light third-party contract manufacturing model.